Compositions and methods for their manufacture and use are provided comprising a soluble extracellular matrix fraction for intravascular delivery which forms a gel or coating in situ for treatment of myocardial infarction and ischemia in a variety of tissues and endothelial injury/dysfunction.

An acellular soft tissue-derived matrix suitable for use as a medical graft or implant may comprise, for example, a delipidated, decellularized adipose tissue matrix. The delipidated, decellularized adipose tissue matrix is substantially free of substances that pose a significant risk of causing an immunogenic response in a patient receiving the matrix. Methods for producing the delipidated, decellularized adipose tissue matrix include the steps of delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting delipidated, decellularized adipose tissue matrix contains a proportion of Type IV collagen which is greater than the proportion of Type IV collagen contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. Additionally, the delipidated, decellularized adipose tissue matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating.

Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

The present invention is directed to a device for the growth of new bone or bone-like tissue under in vitro cell culture conditions.

This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

A method of preparing a decellularized placental membrane is provided. The method comprises removing cells from a pre-decellularized placental membrane comprising an amnion layer and a chorion layer to produce a decellularized placental membrane without separating the amnion layer from the chorion layer. The pre-decellularized placental membrane is obtained from an amniotic sac, and the decellularized placental membrane comprises the amnion layer and the chorion layer. Also provided is a decellularized placental membrane and a placenta-derived graft comprising the decellularized placental membrane. Further provided are the uses of the decellularized placental membrane or the placenta-derived graft.

A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

The present disclosure is directed to a degradable 3D-printable scaffold for use in tissue engineering, which scaffold has a combined gradient and staggered structure. Further provided is a medical device for use in tissue engineering, comprising such a scaffold. The present disclosure also provides a method for preparing a scaffold by additive manufacturing, e.g. 3D-printing, a method for in vivo tissue engineering, use of the scaffold in an in vitro cell culture system, in an in vitro method for culturing of cells and/or in an in vitro method for regenerating tissue. Also provided is a scaffold and a medical device for use in a method for in vivo tissue engineering. Further disclosed is a novel degradable copolymer of ε-caprolactone and p-dioxanone, which can be printed without degradation and which is particularly suitable for use as scaffold material in the scaffold and method according to the present disclosure.

A multi-layer collagen-based membrane that includes a bioresorbable mesh embedded between a first decellularized natural collagen-based membrane and a second decellularized natural collagen-based membrane. The bioresorbable mesh can be formed of a synthetic polymer or demineralized laminar bone. Also provided are two methods for manufacturing a multi-layer collagen-based membrane with or without an embedded bioresorbable mesh.

A method of maintaining cellular viability of harvested bone, where the method includes: providing a source of bone or bone particles; combining the bone or the bone particles with a sterile solution; and storing the bone or the bone particles in the sterile solution until their introduction into a patient.